The Patent Finder
RT

Revance Therapeutics, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Essentia Biosystems, Inc. (to 2009)

28 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
17 more records may belong here and await a decision; they are not counted.

The next US patent term in the Revance Therapeutics, Inc. portfolio ends in Dec 2026, and more of its terms end in 2030 (6) than in any other year. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
17
Ending by 2030
Dec 2026
Next term end
20
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect US 8,926,991
Cited by 34 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Ends Oct 2028 · High confidence
Also notable
Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin US 11,466,262
Cited by 9 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Ends Oct 2030 · Low confidence
Also notable
Albumin-Free Botulinum Toxin Formulations US 9,340,587
Cited by 36 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Ends Sep 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Albumin-Free Botulinum Toxin Formulations (US 11,911,449) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
  • 1 fee due Nov 17, 2027
    The maintenance fee for Albumin-Free Botulinum Toxin Formulations (US 9,340,587) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 24, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,628,756Arginine Heteromers for Topical Administration
In force
 · High confidence
In forceHigh confidence
US 8,241,640Pharmaceutical Botulinum Toxin Compositions
In force
 · High confidence
In forceHigh confidence
US 8,815,954Arginine Heteromers for Topical Administration
In force
 · High confidence
In forceHigh confidence
US 8,691,769Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections
In force
 · High confidence
In forceHigh confidence
US 8,398,997Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
In force
 · High confidence
In forceHigh confidence
US 8,580,317Compositions and Methods for Treating Acne
In force
 · High confidence
In forceHigh confidence
US 8,926,991Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
In force
 · High confidence
In forceHigh confidence
US 8,192,979Compositions, Methods and Devices for Preparing Less Painful Botulinum Toxin Formulations
In force
 · High confidence
In forceHigh confidence
US 8,404,249Compositions and methods for topical application and transdermal delivery of botulinum toxins
In force
 · High confidence
In forceHigh confidence
US 9,950,042Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
In force
 · High confidence
In forceHigh confidence
10 of 28 patents shown.
Pro members see all 28.
Pro members: see all 28 patents
Also on record, not counted in the 28: 23 patents ended · 13 applications pending · 60 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited